Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.4M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
63.6M
-
Shares change
-
+1.35M
-
Total reported value, excl. options
-
$953M
-
Value change
-
+$19.5M
-
Put/Call ratio
-
0.57
-
Number of buys
-
80
-
Number of sells
-
-42
-
Price
-
$14.97
Significant Holders of Spyre Therapeutics, Inc. - Common Stock (SYRE) as of Q2 2025
151 filings reported holding SYRE - Spyre Therapeutics, Inc. - Common Stock as of Q2 2025.
Spyre Therapeutics, Inc. - Common Stock (SYRE) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.6M shares
.
Largest 10 shareholders include FMR LLC (9.05M shares), Fairmount Funds Management LLC (4.02M shares), BlackRock, Inc. (4.01M shares), RTW INVESTMENTS, LP (3.62M shares), TANG CAPITAL MANAGEMENT LLC (3.2M shares), VANGUARD GROUP INC (3.07M shares), VR ADVISER, LLC (2.69M shares), BRAIDWELL LP (2.58M shares), Capital International Investors (2.39M shares), and Driehaus Capital Management LLC (2.09M shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.